Navigation Links
VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
Date:2/28/2011

A issued the CRL to communicate its decision that the NDA could not be approved in its present form.  The CRL included the following areas: clinical, labeling, REMS, safety update, and drug scheduling.  We held a meeting with the FDA on January 19, 2011, to discuss the items contained in the CRL.  At this meeting the FDA requested that we assess the feasibility of performing a retrospective observational study utilizing existing healthcare databases to review fetal outcomes in the offspring of women who received 100mg of topiramate for migraine prophylaxis during pregnancy. In the QNEXA studies, which included 15 births from women exposed to topiramate, there were no reports of any adverse fetal outcomes.

We expect to reach agreement with the FDA, and if deemed feasible, initiate the retrospective observational study on fetal outcomes within the next two months.  We will provide more details as soon as an agreement is reached.  It is our goal to resubmit the NDA for QNEXA by the end of 2011.

Although no other requests for additional information or studies were made by the FDA at the meeting, there can be no assurances that the FDA will not request or require us to provide additional information or undertake additional studies in connection with the QNEXA NDA.  

"In 2010, we also made significant progress with the development of QNEXA as a treatment for obesity by filing for approval in the European Union, and for avanafil we completed the pivotal phase 3 studies," stated Leland Wilson, chief executive officer of VIVUS. "We are working diligently on responding to the FDA's request to assess the feasibility of conducting a retrospective observational study. Our goals for 2011 include the continued advancement towards approval of QNEXA in the US and the EU and filing the NDA for avanafil."

Fourth Quarter ResultsIn November 2010, we sold MUSE and the related assets.  Accordingly, all historical financial
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced ... of common stock and warrants at a price of ... prior to deducting underwriting discounts and commissions and offering ... are immediately separable and will be issued separately.  The ... on The NASDAQ Stock Market under the ticker symbol ...
(Date:8/21/2014)... --  Memorial Hermann Health System and The University ... new partnership to provide a new level of specialized breast ... the greater Houston area. ... provider of professional breast radiology services for five of Memorial ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... , Aug. 21, 2014 Nektar ... International Inc. today announced positive results from its ... an investigational, extended half-life recombinant factor VIII (rFVIII) ... Factor (Recombinant)], which met its primary endpoint in ... arm compared to the on-demand arm. ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... Johnson & Johnson Pharmaceutical,Research & Development, ... demonstrate doripenem (DORIBAX(TM), doripenem for injection), a,carbapenem ... in vitro against certain,strains of Enterobacteriaceae, including ... Enterobacteriaceae is a large group of ...
... A doctor who is,internationally recognized for her ... DHA, an omega-3 fatty acid, has received the,March ... in the field,of maternal-fetal nutrition., Susan E. ... that infants,receiving breast milk had higher DHA (dietary ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition 2
(Date:8/23/2014)... 23, 2014 Professional kitchen employees, prospective ... aid in preparing for Food Safety Certification exams thanks ... by Dynamic Path. , Dynamic Path announced the release ... more than 200 review questions for culinary industry students ... to cover requirements of the ServSafe® Food Safety Certification, ...
(Date:8/23/2014)... Teen drug and alcohol abuse is ... in Wilmington, NC. Substance abuse can happen to people ... drug and alcohol dependency in higher numbers than ever ... substance abuse, but don’t know where to find professional ... be a challenge because most treatment options are designed ...
(Date:8/22/2014)... 2014 Deep Research Report on ... in-depth research report on the Glucose Meter market. ... Glucose Meter definition, classification, application, and industry chain ... covers the international market analysis, including domestic market ... environment & economic situation analysis. The report on ...
(Date:8/22/2014)... 23, 2014 Top 10 Best ... web hosting companies and highly recommended FatCow ( ... The manager of Top 10 Best SEO Hosting ... dedicated server hosting supplier. Actually, these companies have ... speed and customer support. People can get the ...
(Date:8/22/2014)... 2014 With the stage set for ... Store Expo - which will be held in Boston ... op-ed in its online opinion section, Podium. The ... is co-authored by Steven C. Anderson, IOM, CAE, president ... of the MCPHS University School of Pharmacy – Worcester/Manchester. ...
Breaking Medicine News(10 mins):Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3
... led by Dr. Bernhard Hering have reported the arrival of ... new $6.2 million, 21,000-square-foot Islet Resource Facility in Minneapolis, U.S. ... project- the Spring Point Project, a non- profit organization for ... ,This project will focus on the testing of ...
... 36-year-old professional body-builder who used growth hormone to boost his ... to a report. ,He was admitted with chest ... 12 months, during which he had also experienced excessive urination, ... for 15 years and artificial growth hormone for the past ...
... - The FDA has permitted the use of a ... drug known as Vyvanse//, is manufactured by Shire PLC. ... have a smooth transition from the older ADHD medications ... that the present drug is promising because it is ...
... doctors in Srinagar are quite frustrated by the large number ... bite cases// recorded by the main SMHS hospital here last ... in the last two months. 'The situation is alarming. We ... cases the victims are suspected to have been bitten by ...
... are under the impression that ovarian cancer can be detected ... that this wrong notion is more dangerous to the lives ... 610 women, out of which 305 thought that pap smear ... Breast Cancer Centre said that pap smear is not the ...
... education programme on cervical cancer prevention and the new vaccine ... organized by a team of doctors from Obstetrics and Gynecology ... ,Dr Rihab Awad of the hospital insisted on ... tests once a year. Any aberration detected in cervix can ...
Cached Medicine News:Health News:Pigs Arrive at Bio-secure Center 2
... a new generation Spectrophotometer for near ... nm to 1020 nm with built-in ... and printer. It features four digit ... transmittance, absorption and concentration with excellent ...
... 400 Series Spectrophotometer is ... to UV-VIS instrumentation. The ... incorporated into a radically ... features and performance unprecedented ...
... 520 General Purpose UV/Vis Spectrophotometer. Beckman ... proven technology for a wide range ... 500 Scanning Spectrophotometers, with easily interchangeable ... use. A totally affordable, completely modular ...
... user to quickly and accurately count bacteria colonies. ... or manual counting. An optional 1.5X auxiliary lens ... 3.0X. The adjustable focusing rod allows the 1.5X ... lens also rotates a full 360 for ready ...
Medicine Products: